NYSE:EBS - Emergent Biosolutions Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $69.74 +0.04 (+0.06 %) (As of 11/20/2018 04:00 PM ET)Previous Close$69.70Today's Range$68.47 - $71.3652-Week Range$37.89 - $71.77Volume354,131 shsAverage Volume344,710 shsMarket Capitalization$3.63 billionP/E Ratio36.71Dividend YieldN/ABeta1.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland. Receive EBS News and Ratings via Email Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNYSE:EBS Previous Symbol CUSIP29089Q10 Webwww.emergentbiosolutions.com Phone240-631-3200 Debt Debt-to-Equity Ratio0.01 Current Ratio5.52 Quick Ratio4.29 Price-To-Earnings Trailing P/E Ratio36.71 Forward P/E Ratio35.22 P/E Growth1.8 Sales & Book Value Annual Sales$560.87 million Price / Sales6.33 Cash Flow$2.7381 per share Price / Cash25.47 Book Value$18.47 per share Price / Book3.78 Profitability EPS (Most Recent Fiscal Year)$1.90 Net Income$82.59 million Net Margins14.19% Return on Equity12.89% Return on Assets10.71% Miscellaneous Employees1,256 Outstanding Shares50,940,000Market Cap$3.63 billion OptionableOptionable Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions What is Emergent Biosolutions' stock symbol? Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." How will Emergent Biosolutions' stock buyback program work? Emergent Biosolutions announced that its Board of Directors has authorized a share repurchase plan on Friday, March 23rd 2018, which authorizes the company to buyback $50,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its shares are undervalued. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc (NYSE:EBS) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by $0.07. The biopharmaceutical company had revenue of $173.70 million for the quarter, compared to analysts' expectations of $185.16 million. Emergent Biosolutions had a net margin of 14.19% and a return on equity of 12.89%. The business's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.73 earnings per share. View Emergent Biosolutions' Earnings History. When is Emergent Biosolutions' next earnings date? Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Emergent Biosolutions. What price target have analysts set for EBS? 7 equities research analysts have issued 1 year price objectives for Emergent Biosolutions' shares. Their predictions range from $60.00 to $80.00. On average, they expect Emergent Biosolutions' stock price to reach $69.2857 in the next year. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Emergent Biosolutions. What is the consensus analysts' recommendation for Emergent Biosolutions? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions. What are Wall Street analysts saying about Emergent Biosolutions stock? Here are some recent quotes from research analysts about Emergent Biosolutions stock: 1. According to Zacks Investment Research, "Emergent BioSolutions recorded high sales for both anthrax vaccine BioThrax as well as smallpox vaccine ACAM2000. The increase in BioThrax sales was primarily owing to the favorable timing of BioThrax deliveries to the SNS. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the company’s cost structure. Shares have outperformed the broader industry so far this year. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturg BioThrax. This in turn, also raises a concern." (11/13/2018) 2. Cantor Fitzgerald analysts commented, ". Post 2Q18, we are reiterating our Overweight rating and 12- month price target of $62. Emergent has successfully established itself as a leader in the biodefense field and has carved out a high-barrier-to-entry niche in that market. We believe the company’s business is a lot more durable than the Street is giving the company credit for. We expect Emergent to extend a number of its current contracts beyond current estimates. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on its products. The company has set a goal of $1B in revenue, which we expect it to reach through the renewal of contracts, pipeline advancements and business development." (8/2/2018) Has Emergent Biosolutions been receiving favorable news coverage? Media headlines about EBS stock have trended positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Emergent Biosolutions earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Emergent Biosolutions' key competitors? Some companies that are related to Emergent Biosolutions include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Alkermes (ALKS) and SAGE Therapeutics (SAGE). Who are Emergent Biosolutions' key executives? Emergent Biosolutions' management team includes the folowing people: Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)Mr. Daniel J. Abdun-Nabi, CEO & Director (Age 63)Mr. Robert G. Kramer Sr., Pres & COO (Age 61)Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 45)Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 47) Who are Emergent Biosolutions' major shareholders? Emergent Biosolutions' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.47%), Renaissance Technologies LLC (3.67%), Dimensional Fund Advisors LP (3.43%), Acadian Asset Management LLC (2.53%), Rice Hall James & Associates LLC (2.23%) and Standard Life Aberdeen plc (2.15%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions. Which major investors are selling Emergent Biosolutions stock? EBS stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Standard Life Aberdeen plc, Dimensional Fund Advisors LP, Man Group plc, Acadian Asset Management LLC, Renaissance Technologies LLC, Glenmede Trust Co. NA and Russell Investments Group Ltd.. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions. Which major investors are buying Emergent Biosolutions stock? EBS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Matarin Capital Management LLC, Neuberger Berman Group LLC, Prudential Financial Inc., FMR LLC, Bank of New York Mellon Corp, Putnam Investments LLC and Morgan Stanley. View Insider Buying and Selling for Emergent Biosolutions. How do I buy shares of Emergent Biosolutions? Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Emergent Biosolutions' stock price today? One share of EBS stock can currently be purchased for approximately $69.74. How big of a company is Emergent Biosolutions? Emergent Biosolutions has a market capitalization of $3.63 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe. What is Emergent Biosolutions' official website? The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com. How can I contact Emergent Biosolutions? Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected] MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 298 (Vote Outperform)Underperform Votes: 245 (Vote Underperform)Total Votes: 543MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What is Cost of Capital?